# Exploratory Clinical Study of CD19-targeted CAR-T and CAR-DC in the Treatment of Relapsed and Refractory B-cell Lymphoma

> **NCT05585996** · PHASE1 · UNKNOWN · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 70 (estimated)

## Conditions studied

- Relapsed and Refractory B-cell Lymphoma

## Interventions

- **BIOLOGICAL:** CD19 CAR-T and CD19 CAR-DC

## Key facts

- **NCT ID:** NCT05585996
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-08-01
- **Primary completion:** 2025-11-01
- **Final completion:** 2025-12-30
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2023-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05585996

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05585996, "Exploratory Clinical Study of CD19-targeted CAR-T and CAR-DC in the Treatment of Relapsed and Refractory B-cell Lymphoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05585996. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*